ImmuneRegen BioSciences' Homspera(TM) Deemed Dermally Non-Toxic Pre-Clinical Studies Bode Well for Future Hair Loss Applications SCOTTSDALE, Ariz., March 3 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBH) , today announced their toxicity study for their proprietary compound Homspera showed no levels of toxicity, such as skin irritation, in tested animals. With these results, the company is moving forward in targeting male pattern baldness as a potential application for Homspera. The study was performed by AppTec Laboratory Services of St. Paul, MN and was designed to evaluate the allergenic potential or sensitizing capacity for the company's substance P compound. According to the AppTec results report, "ImmuneRegen BioSciences, Inc., Homspera [Sar9, met (O2)11] -- Substance P ... was classified as acceptable in regard to dermal sensitization." "Obviously we're thrilled with these test results," states Michael K. Wilhelm, president of IR BioSciences Holdings, Inc. "We're currently researching the effectiveness of Homspera in topical applications for conditions such as male pattern baldness and loss of hair from chemotherapy. These results put us one stepcloser to making these applications a reality." About the study The study utilized fifteen guinea pigs, ten experimental and five controls. Patches with topical doses of Homspera [Sar9, met (O2)11] -- Substance P were applied to the shaved left flanks of the ten experimental guinea pigs, which were then bandaged to secure the patches. The bandaging and patches were removed after six to eight hours of exposure and each guinea pig was checked after roughly 24 hours for signs of erythema and edema. The procedure was repeated once a week for three weeks for a total of three inductions. The tested guinea pigs showed no signs of erythema or edema. Fourteen days after completing the topical induction process, patches with topical doses were appliedto the shaved right flanks of the ten experimental guinea pigs, which were then bandaged to secure the patches. Again, the bandaging and patches were removed after six to eight hours of exposure. At the 24, 48 and 72-hour marks, each testing area waswiped gently with a 70% isporpyl alcohol-soaked gauze sponge and was observed for irritation and sensitization reactions. Again, the tested guinea pigs showed no signs of erythema or edema. About AppTec AppTec Laboratory Services is a unique single source for the biopharmaceutical/biotechnology and medical device/medical product industries -- offering testing, contract research and development, and specialized cGMP manufacturing services. About IR BioSciences Holdings, Inc. IR BioSciences Holdings, Inc. (OTC:IRBH) (BULLETIN BOARD: IRBH) , formed in 2003, is the sole owner of ImmuneRegen BioSciences, Inc., a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, ImmuneRegen has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the company's website at http://www.immuneregen.com/ . About Homspera ImmuneRegen's patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Mark Witten and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke. Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company's periodic report on Form 8-K as filed with the Securities and Exchange Commission on July 7, 2003. DATASOURCE: ImmuneRegen BioSciences, Inc. CONTACT: Media, Michelle Derden of Spelling Communications, +1-310-477-9500, ; or Investors, Tony Schor of InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen BioSciences, Inc. Web site: http://www.immuneregen.com/

Copyright